ArticleBMJ open respiratory research2026
Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA patient pathway is an evidence-based tool that details the phases of care with the aim of increasing the effectiveness and efficiency of patient care. We describe diagnostic and treatment pathways and related overall survival (OS) of non-small cell lung cancer patients.
methodsThis was a longitudinal, historical descriptive cohort study based on administrative claim data, spanning from 2017 to 2022. The index date was determined by the first bronchoscopy with lung biopsy (BX) followed by histopathological (HP) examination, alongside the presence of the International Classification of Diseases 10th revision diagnosis code C34. Incident patients aged ≥18 without prior malignancy. Pharmacotherapies (PHT), including chemotherapy (PHT_CT), precision therapy (PHT_IOTT), as well as surgery (SX) and radiotherapy (RT), were investigated associated with OS. A presence of multidisciplinary team (MDT) and treatment at a Complex Oncological Center (COC) with high-load experience was considered.
resultsWe analysed 5819 patient pathways. Less than half (45.6%) of patients had MDT reported within a median of 20 days. Of the 4417 patients treated, 30% underwent more than one BX, 47.7% received PHT_CT, 25.9% underwent SX, 16.4% underwent RT and 9.08% PHT_IOTT. Early initiation of treatment within 4 weeks from BX was identified in 21% of SX patients, 30% of patients treated with PHT_CT and 23% of RT patients. The centralisation of care in COCs primarily concerned SX and PHT_IOTT, while 33% of patients indicated to PHT_CT were treated elsewhere. The median OS reached approximately 16 months in the overall population, 21 months in the verified treated cohort and 13 months in patients treated with PHT_CT, while it was not reached in patients treated with SX. We observed a positive association between patient prognosis and treatment centralisation in COCs.
conclusionsThis methodology can be implemented as a technical infrastructure to fulfil the organisation and quality evaluation routines in cancer care, largely based on administrative data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.